1 Stock Under $65 That You Shouldn’t Ignore

Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should…

BBIG Stock Is Gaining Popularity, but Does That Mean It’s a Buy?

Vinco Ventures (BBIG) has come into the spotlight recently due to its short-squeeze-driven rally despite possessing weak fundamentals. Is this meme stock a buy because of its increasing popularity among…